Bilifalk (Ursodiol) Therapeutic Domains

Bilifalk, containing the active substance ursodiol, is indicated for specific therapeutic needs related to the liver and gallbladder. Its uses center on addressing bile acid composition and flow in certain conditions.

---

Quick Facts

• Addresses: Primary Biliary Cholangitis (PBC), a type of chronic liver disease.
• Facilitates: The dissolution of radiolucent (non-calcified) gallstones in select patients who face increased surgical risk or for whom cholecystectomy is not feasible.
• Supports: The prevention of gallstone formation in patients undergoing rapid weight reduction.

---

Main Uses and Benefits

Ursodiol is principally utilized in the management of Primary Biliary Cholangitis (PBC). For patients diagnosed with this chronic liver condition, treatment with ursodiol contributes to improved liver function test markers and may assist in delaying disease progression.

Additionally, Bilifalk offers a pathway for the non-surgical management of cholesterol-based gallstones, specifically those that are smaller and non-calcified. For individuals undergoing rapid weight loss, the medication is also used to reduce the likelihood of new gallstone development.

Regulatory References

1. EMA therapeutic overview

Official Population Eligibility for Bilifalk (Ursodiol)

Eligibility to use Ursodiol is strictly defined by regulatory authorities based on specific patient conditions and demographic factors, rather than general health status.

---

Absolute Non-Eligibility (Contraindications)

Patients must not use this medicine if they have:

• Hypersensitivity to bile acids (ursodiol) or any other component.
• Complete biliary tract obstruction (e.g., in the cystic or common bile duct).
• Radio-opaque calcified gallstones, as the medicine is only indicated for non-calcified, cholesterol stones.
• Decompensated hepatic cirrhosis (advanced stage of liver disease).
• Active inflammation of the gallbladder or biliary tract.

---

Restricted and Conditional Use

Population Group	Regulatory Status and Condition
Pediatric Patients	Safety and effectiveness are not established for general pediatric use; use is limited to specific labeled indications (FDA).
Women of Childbearing Age	Must use effective non-hormonal contraception when taking the medicine for gallstone dissolution (EMA, FDA).
Pregnancy/Lactation	Use only if clearly needed; caution is advised during breastfeeding due to lack of comprehensive data (FDA, Health Canada).
Gallbladder Function	Contraindicated if the gallbladder has impaired contractility (EMA, FDA).
Adverse Reaction	Treatment must be discontinued if severe, persistent diarrhea occurs (EMA, FDA).

Bilifalk (Ursodiol) Interactions with other medicines and products

When taking Bilifalk (ursodiol), it is essential to be aware of potential drug interactions that may affect its efficacy or increase the risk of side effects. Ursodiol absorption can be reduced by certain medicines, requiring careful timing or dosage adjustments.

---

Key Drug Interactions

Interacting Drug Class	Effect on Ursodiol	Example Medicines
Bile Acid Sequestrants	Decrease absorption. These bind to ursodiol in the intestine.	Cholestyramine, Colestipol
Aluminum-containing Antacids	Decrease absorption. Should be taken at a different time.	Certain Antacids (e.g., Maalox, Mylanta)

---

️ Other Notable Interactions

Ursodiol may potentially affect the absorption or activity of other medicines. For example, it may increase the absorption of cyclosporine, requiring monitoring and possible dosage adjustment of the immunosuppressant.

Additionally, drugs like estrogens, oral contraceptives, and certain lipid-lowering agents (such as clofibrate) may increase cholesterol secretion into the bile. This counteracts the effects of ursodiol, which is often used to dissolve cholesterol gallstones, potentially making the treatment less effective.

Always inform your healthcare provider about all prescription drugs, over-the-counter medicines, and herbal supplements you are currently taking.

Cholesterol Solubilization and Bile Pool Modification

Ursodiol alters the chemistry of bile by inhibiting the secretion of cholesterol from the liver and increasing its capacity to be held in solution. The drug forms unique liquid crystals within the bile, fundamentally changing the fluid's solvent characteristics. This action results in the physiological consequence of undersaturating the bile, which supports the resultant breakdown of solid cholesterol structures.

️ Hepatocyte Cytoprotection and Detoxification

Ursodiol exerts a cytoprotective mechanism by engaging in competitive displacement, becoming the dominant, hydrophilic bile acid in circulation and replacing the more harmful, hydrophobic forms. This interaction stabilizes the hepatocyte and cholangiocyte membranes, including the mitochondria, thus interrupting the apoptotic (cell death) cascades triggered by chemical stress. This leads to the preservation of cell viability and a resultant decrease in the chemical stress exerted on the liver.

Biliary Flow Enhancement and Immune Dampening

The drug acts as a choleretic agent by modulating membrane transporters to stimulate the secretion of water and electrolytes, enhancing the total volume and flow of bile. Simultaneously, it engages in local immunomodulation by reducing the expression of MHC Class I antigens on liver cells. This coordinated mechanism facilitates the enhanced clearance of bile components and reduces the local expression of inflammatory signals within the liver tissue.

How to Use Bilifalk (Ursodiol)

Ursodiol (Bilifalk) is administered strictly via the oral route, available as capsules, tablets, or an oral suspension. The precise usage pattern depends heavily on the condition being addressed, necessitating careful adherence to the official dosing regimen.

Official Administration Guidelines

Usage Instruction	Details
Dosing Schedule	Dosing is weight-based. For Primary Biliary Cholangitis (PBC), the typical daily range is 13–15 mg/kg. For Gallstone Dissolution, the range is 8–12 mg/kg per day.
Dosing Frequency	The total daily dose for gallstone dissolution is taken once daily in the evening (e.g., at bedtime). For PBC, the total daily dose is typically divided into 2 to 4 doses initially, which may be consolidated later to a single dose in the evening.
Administration Context	The daily dose for PBC treatment is usually taken with food. Capsules and tablets must be swallowed whole with liquid and should not be chewed. Scored tablets are designed to be broken in half for flexible dosing.

Treatment Course and Population Rules

Therapy for PBC is considered long-term and may be continued indefinitely. Conversely, gallstone dissolution treatment typically lasts between 6 to 24 months. This course must be continued for an additional 3 months after imaging confirms the stones are fully dissolved.

Pediatric Dosing for Cystic Fibrosis-associated liver disorders follows a different, weight-based divided daily regimen of 20 mg/kg up to 30 mg/kg. If a dose is missed, it should be taken when remembered, unless it is near the time for the next scheduled dose, in which case the missed dose should be skipped; a double dose must never be taken.

Research Evidence / Overview of Studies for Bilifalk (Ursodiol)

---

Evidence for Use in Primary Biliary Cholangitis (PBC)

Research has focused on the evaluation of Ursodiol for patients with Primary Biliary Cholangitis (PBC), a chronic condition marked by functional limitations. This research includes long-term Randomized Controlled Trials (RCTs) and extensive observational cohort studies, monitoring changes over defined time intervals. Studies monitored the observed patterns relating to hard clinical outcomes, specifically the time until an event such as a liver transplantation or death. Studies examined how measurements of biochemical markers like Bilirubin and Alkaline Phosphatase (ALP) evolved in the Ursodiol groups compared to controls. Research on patient-reported outcomes, such as fatigue and pruritus (itching), has shown limited or non-significant change in the observed populations.

---

Evidence for Gallstone Dissolution and Prevention

Studies examined Ursodiol's role in the dissolution of cholesterol-based gallstones that are radiolucent (non-calcified). The research focused on the gallstone dissolution rate and monitored stone recurrence after treatment cessation. Research reported that the observed rate of dissolution varied depending on factors such as the size and composition of the stones.

Research has also explored whether Ursodiol has an association with the formation of new gallstones in individuals undergoing rapid weight reduction. Placebo-controlled trials monitored the incidence of new gallstone formation. These studies are predominantly short-term, focused on observation periods of approximately 6 to 12 months post-intervention. There is limited information for long-term outcomes regarding the durability of the preventative pattern or the risk of recurrence without ongoing research.

---

What is Still Uncertain About Bilifalk (Ursodiol)

A primary limitation is that research on patient-reported outcomes (e.g., fatigue and pruritus in PBC) has shown limited or mixed findings. Furthermore, evidence quality varies across studies; findings were mixed in some early trials regarding the most complex outcome, which is the time until death or liver transplantation. The evidence is limited for gallstone dissolution, as the research only applies to a highly specific subset of patients. Overall, research provides context but not individual predictions, and data for certain groups remain limited.

Key Studies & References

1. Ursodeoxycholic Acid Label Information and Product Monograph (Regulatory Documentation)
2. Management of Gallstones and Gallstone Complications (Clinical Monograph)

Common questions about Bilifalk (Ursodiol) (FAQ)

Q: What is Bilifalk (Ursodiol) used for?

A: Bilifalk (Ursodiol) is primarily used to dissolve cholesterol gallstones in people who have a functioning gallbladder and for whom surgery is not suitable. It is also used to treat the symptoms of Primary Biliary Cholangitis (PBC), a chronic liver disease.

Q: How does Bilifalk (Ursodiol) work?

A: Ursodiol is a naturally occurring bile acid. It works by decreasing the amount of cholesterol produced by the liver and absorbed by the intestines. This allows it to dissolve cholesterol gallstones by reducing the saturation of cholesterol in bile. In the case of PBC, it is thought to work by altering the composition of the bile acid pool, protecting liver cells from the toxic effects of other bile acids.

Q: How long does it take for Bilifalk to dissolve gallstones?

A: The time required for gallstone dissolution varies significantly among individuals. It can take anywhere from 6 months to 2 years of continuous treatment. Treatment must typically be continued for about three months after the gallstones are confirmed to be dissolved by ultrasound or X-ray. Your healthcare provider will monitor your progress regularly.

Q: What are the common side effects of Bilifalk (Ursodiol)?

A: The most common side effects reported are generally mild and may include:

• Gastrointestinal issues: Diarrhea, loose stools, and nausea.
• Other common effects: Hair loss, rash, and itching.

If you experience severe diarrhea, contact your healthcare provider immediately, as a dose reduction may be necessary.

Q: Can Bilifalk (Ursodiol) be taken with food?

A: Yes, it is generally recommended to take Bilifalk (Ursodiol) with a meal or snack to help with absorption. However, always follow the specific instructions provided by your healthcare provider.

Q: What should I avoid while taking Bilifalk (Ursodiol)?

A: Avoid taking aluminum-containing antacids (like those containing aluminum hydroxide) at the same time as Bilifalk, as they can bind to the medicine and reduce its effectiveness. If you need to take an antacid, separate the doses by at least 2 hours.

Certain cholesterol-lowering medications (like cholestyramine or colestipol) can also reduce the absorption of ursodiol; these should be spaced out from your ursodiol dose.

Avoid taking estrogen-containing oral contraceptives or hormone replacement therapy, as estrogens can increase the cholesterol content of bile, which might counteract the effect of ursodiol.

Storage and Disposal of Bilifalk (Ursodiol)

Ursodiol must be stored in a closed container at controlled room temperature, generally defined as 20 C to 25 C (68 F to 77 F). The storage environment must protect the product from moisture, and the medication must not be frozen. Any unused medicine must be kept out of the sight and reach of children.

For stability, if tablets are broken, the remaining half-tablets must be stored in the original medicine bottle and used or discarded within 28 days. When disposing of expired or unused product, it is prohibited to place it in household trash or wastewater; disposal must adhere to local requirements for pharmaceutical waste.